Brokerages Expect Intellia Therapeutics Inc (NASDAQ:NTLA) to Announce -$0.53 Earnings Per Share

Brokerages expect that Intellia Therapeutics Inc (NASDAQ:NTLA) will report earnings of ($0.53) per share for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Intellia Therapeutics’ earnings, with estimates ranging from ($0.64) to ($0.47). Intellia Therapeutics posted earnings of ($0.43) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 23.3%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, February 26th.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

On average, analysts expect that Intellia Therapeutics will report full year earnings of ($2.09) per share for the current year, with EPS estimates ranging from ($2.31) to ($1.97). For the next year, analysts anticipate that the company will post earnings of ($2.28) per share, with EPS estimates ranging from ($3.00) to ($1.71). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Intellia Therapeutics.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.12. Intellia Therapeutics had a negative return on equity of 33.00% and a negative net margin of 225.54%. The company had revenue of $10.60 million for the quarter, compared to analyst estimates of $9.17 million. During the same period in the previous year, the company posted ($0.53) earnings per share. The firm’s revenue was up 43.2% on a year-over-year basis.

A number of analysts recently commented on NTLA shares. Raymond James upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $24.00 price objective for the company in a research report on Friday, November 1st. Chardan Capital set a $57.50 price objective on Intellia Therapeutics and gave the company a “buy” rating in a research report on Friday, September 27th. BidaskClub upgraded Intellia Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 2nd. Zacks Investment Research upgraded Intellia Therapeutics from a “hold” rating to a “strong-buy” rating and set a $15.00 price objective for the company in a research report on Wednesday. Finally, ValuEngine cut Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $24.94.

Shares of NASDAQ NTLA traded up $0.22 during mid-day trading on Thursday, hitting $13.15. 558,600 shares of the stock traded hands, compared to its average volume of 559,375. The company has a market cap of $625.20 million, a price-to-earnings ratio of -6.64 and a beta of 2.68. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.89 and a current ratio of 7.89. Intellia Therapeutics has a 52 week low of $10.26 and a 52 week high of $19.38. The stock has a fifty day moving average price of $12.21 and a 200-day moving average price of $14.87.

A number of institutional investors and hedge funds have recently modified their holdings of NTLA. Benjamin Edwards Inc. increased its position in Intellia Therapeutics by 60.9% in the second quarter. Benjamin Edwards Inc. now owns 1,691 shares of the company’s stock worth $28,000 after buying an additional 640 shares in the last quarter. Bank of Montreal Can increased its position in Intellia Therapeutics by 406.5% in the second quarter. Bank of Montreal Can now owns 3,824 shares of the company’s stock worth $63,000 after buying an additional 3,069 shares in the last quarter. Mizuho Securities Co. Ltd. purchased a new stake in Intellia Therapeutics in the second quarter worth about $64,000. Aperio Group LLC purchased a new stake in Intellia Therapeutics in the second quarter worth about $83,000. Finally, Resources Investment Advisors LLC. increased its position in Intellia Therapeutics by 60.2% in the second quarter. Resources Investment Advisors LLC. now owns 8,648 shares of the company’s stock worth $142,000 after buying an additional 3,250 shares in the last quarter. Institutional investors and hedge funds own 83.61% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.

See Also: After-Hours Trading

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Leave a Reply

Your email address will not be published. Required fields are marked *